Cost-effectiveness of a 12-month fixed-duration venetoclax treatment in combination with obinutuzumab in first-line, unfit chronic lymphocytic leukemia in the United States
在美国，一线治疗不适合接受其他治疗的慢性淋巴细胞白血病患者，采用 12 个月固定疗程的维奈托克联合奥妥珠单抗治疗的成本效益分析
期刊:
影响因子:
doi:10.18553/jmcp.2021.27.11.1532
Chatterjee, Anuja; Shapouri, Sheila; Manzoor, Beenish S; Ravelo, Arliene; Sail, Kavita; Qendri, Venetia; van de Wetering, Gijs; Davids, Matthew S
